Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study
G Bayer, MS Agier, B Lioger, M Lepelley… - European journal of …, 2019 - Elsevier
Introduction Rituximab induced serum sickness (RISS) is a rare delayed hypersensitivity
reaction. The aim of this study was to describe the epidemiological and clinical
characteristics of the RISS cases reported in France. Method Serum sickness cases
involving rituximab were identified from the French PharmacoVigilance Database from 1998
to 2016. Results We analyzed 37 cases of RISS. Rituximab was prescribed for an
autoimmune disease in 78% of cases. Serum sickness occurred mainly after the first …
reaction. The aim of this study was to describe the epidemiological and clinical
characteristics of the RISS cases reported in France. Method Serum sickness cases
involving rituximab were identified from the French PharmacoVigilance Database from 1998
to 2016. Results We analyzed 37 cases of RISS. Rituximab was prescribed for an
autoimmune disease in 78% of cases. Serum sickness occurred mainly after the first …
